382 results about "Senescent cell" patented technology

The invention relates to compositions (e.g., pharmaceutical compositions), uses, methods, non-therapeutic and therapeutic methods related to senolytic agents encapsulated or comprised in Muse cell derived extracellular vesicles (e.g. exosomes). Such compositions and methods are useful for specifically killing senescent cells and reverting any symptoms, disorders or diseases associated with senescence.

The invention discloses a ginseng extract rich in rare saponins and preparation and anti-aging application thereof, and belongs to the technical field of oral beauty and skin care products, the ginseng extract is obtained by fermentation treatment of ginseng powder through phytobacterium plantarum, and the preservation number of the phytobacterium plantarum is GDMCC No.64374. The ginseng extract rich in rare saponin is fermented by specific plant lactobacillus, ginsenoside is efficiently converted into CK and F1, various natural plant components such as ginseng polysaccharide are reserved, and a specific synergistic effect is generated. Through verification, the prepared ginseng extract is high in bioavailability, can more effectively inhibit cell inflammation, and can more effectively recover the mitochondrial function of senescent cells and inhibit cell senescence. The preparation method provided by the invention is high in operability and easy to standardize and intellectualize. Compared with a traditional extraction and purification method, the adopted fermentation method is more environmentally friendly and efficient, and large-scale production can be achieved in industrial production.

The invention discloses a medicine for targeting senescent cells to stimulate endogenous immunity and application of the medicine, and relates to the field of biological medicine. The medicine provided by the invention can mediate the interaction between senescence cells and immune cells, enhance the endogenous immune function, and achieve the purposes of effectively removing senescence cells and improving senescence-related diseases. According to the functional molecule for targeted aging cell immune sensitization, one end of the molecule targets an aging cell membrane molecule, glutamic acid is used for marking the surface of an aging cell, coupling between an endogenous immune cell and the aging cell is mediated, and adhesion and removal of the aging cell by the immune cell are promoted. The molecule can regulate the immune microenvironment of senescence tissues, effectively reduce the number of positive senescence cells of senescence-related beta-galactosidase, reverse fibrosis and improve natural senescence phenotypes.

To provide senolytic agents to eliminate senescent cells and methods for treating diseases and disorders associated with senescence.SOLUTION: Disclosed is a method for removing senescent cells from banked stem cells, the method comprising adding to the stem cells at least one senolytic agent. Also provided is a pharmaceutical composition comprising at least one senolytic agent for use in a method for treating a disease, disorder or condition associated with senescence in a subject, where the method comprises removing stem cells from the subject, culturing the cells with the pharmaceutical composition, and administering to the subject the cultured cells.SELECTED DRAWING: None

Described herein are methods and compositions for use in treating, preventing or reversing aging or age-related diseases, disorders or conditions. Also, described herein are methods and compositions for selective killing of senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies, diseases and conditions. As disclosed herein are methods where senescent cell associated diseases and disorders may be treated or prevented (i.e., likelihood of occurrence or development is reduced) by administering the described compositions.

A fibroblast activation protein (FAP) targeting chimeric antigen receptor macrophage and its construction method and application. The expression of FAP increases in senescent cells of various senescent diseases. Immune cells, especially macrophages, specifically eliminates senescent cells after expressing chimeric antigen receptor recognizing FAP protein, thereby reducing the pathogenic effect of senescent cells. Macrophages expressing the FAP chimeric antigen receptor can undergo M2-type polarization, which do not produce inflammatory factors to deteriorate age related diseases, have good infiltration ability to tissues with dense matrix, do not induce graft-versus-host disease and have high recognition efficiency of senescent cells and good phagocytic effect. This provides a new idea for preparing reagents for eliminating senescent cells, which have wide potential in practical application.

The invention provides a probe for cell senescence analysis and a preparation method and application thereof, and belongs to the technical field of cell detection. The invention discloses a probe for cell aging analysis. The probe comprises fusion protein formed by fibronectin RGD and fluorescent protein, the fibronectin RGD is a polypeptide fragment containing an amino acid sequence as shown in SEQ ID NO: 1. The probe is fixed on a solid-phase carrier and then co-incubated with cells to be detected, the condition of senescent cells can be analyzed and judged by detecting the intensity of a fluorescence signal, the purpose of rapid analysis is achieved, the analyzed cells can be recycled and then continuously cultured, the detection cost is low, and the probe is suitable for large-scale popularization and application in the market.

The invention discloses glycosylated ganoderic acid with a chemical structural formula shown in the specification, the compound can effectively improve H2O2-induced cellular morphological change, remarkably reduce generation of reactive oxygen species (ROS) and reduce accumulation of beta-galactosidase in senescent cells, and in addition, cell immunoblotting analysis shows that the compound can be used for preparing glycosylated ganoderic acid. The glycosylated ganoderic acid can significantly down-regulate the expression of H2O2-induced senescence marker proteins p16 and p21, and experimental results prove that the glycosylated ganoderic acid has potential in the aspect of reversing cell senescence, provides a new candidate compound for the development of anti-senescence drugs, and shows a wide application prospect; # imgabs0 #

Provided is a novel pharmaceutical composition for treating or preventing an aging-related disease by utilizing selective removal of a senescent cell. A pharmaceutical composition comprising an anti-integrin α11 (ITGA11) antibody as an active ingredient is administered to a subject.

The invention discloses a senescent cell recognition system and method based on mitochondrial morphology. The system is a classification network, and the input data of the system is a distribution image of mitochondria in subcellular level cells, the distribution image of mitochondria in cells, the shape and / or number of mitochondria distributed at different positions in a three-dimensional structure for displaying cells, and preferably the shape and number of mitochondria distributed at different positions in the three-dimensional structure for displaying cells. According to the senescence cell recognition system based on the mitochondrial morphology, the senescence cells jointly show mitochondrial morphological changes including mitochondrial distribution, mitochondrial shapes and mitochondrial number changes, the senescence cell recognition method is easy to conduct through computer vision, good robustness is achieved, and the senescence cell recognition system based on the mitochondrial morphology is suitable for being applied to senescence cell recognition. Compared with other senescence cell identification methods based on cell nucleus morphological characteristics, the senescence cell identification method based on the general characteristics of the senescence cells has good universality for different cell types.

[Problem] To provide a novel ferroptosis-inducing drug, and in particular, to provide a ferroptosis induction promoter that can effectively promote the induction of ferroptosis even in a cell having ferroptosis resistance even in a ferroptosis-inducing environment (for example, cancer cells and senescent cells). [Solution] Provided is a ferroptosis induction promoter comprising a drug that can reduce lysosomal pH.

The present invention belongs to the technical field of gene therapy. Provided are a chimeric antigen receptor nanocomposite and a preparation method therefor and the use thereof in the preparation of an anti-aging drug. The provided chimeric antigen receptor nanocomposite comprises a chimeric antigen receptor DNA plasmid specifically recognizing senescent cells, a polymer coupled with a signal peptide, a free polymer and an antibody polymer targeting T cells, wherein the chimeric antigen receptor DNA plasmid, the polymer coupled with a signal peptide, the free polymer and the antibody polymer targeting T cells are sequentially mixed and incubated to form the chimeric antigen receptor nanocomposite. The chimeric antigen receptor nanocomposite can rapidly generate senescent cell-marked chimeric antigen T cells in vivo. The engineered T cells have the ability to specifically eliminate senescent cells in vivo, and can rapidly and durably eliminate senescent cells in vivo, which is irreplaceable and has wide application prospects.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair fixing and hair loss preventing composition comprises 17-type collagen, a plant extract and adenosine substances, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

The invention discloses a galactose-masked aminoquinoline compound and application thereof, the structural formula of the galactose-masked aminoquinoline compound is # imgabs0, and R is acetyl, propionyl or butyryl. After being subjected to hydrolysis deacetylation, propionylation or butyrylation by esterase in cells, the compound can be activated by senescence-related beta galactosidase in senescence cell lysosome to release aminoquinoline (NCQ) so as to inhibit the survival of senescence cells in vivo or in vitro.

The invention discloses an anti-aging longevity and qi-boosting soup composition and its use, comprising the following raw materials or extracts of raw materials in parts by weight: 9-30 parts of Radix Pseudostellariae, 9-30 parts of Poria, 6-20 parts of Angelicae Sinensis, 6-20 parts of stir-fried Semen Ziziphi Spinosae, 6-15 parts of Radix Ophiopogonis, 3-15 parts of roasted Polygala Tenuifolia, 10-60 parts of Longan Meat, 10-30 parts of Radix Rehmanniae, 9-30 parts of Scrophulariae, 3-20 parts of Acorus Gramineus, 9-30 parts of Semen Platycladi, 15-30 parts of roasted Plastron Tortoise, 15-30 parts of calcined Dragon Bone, 6-30 parts of Lotus, and 3-60 parts of Licorice. The composition can inhibit the activity of aging markers β-galactosidase in cells and animals, the expression of P16 or P21, remove senescent cells, improve the antioxidant capacity of cells and animals, reduce the expression level of inflammatory factors in cells and animals, and has a significant anti-aging effect.

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair-fixing and hair-loss-preventing composition comprises 17-type collagen, a plant extract and a peptide substance, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention relates to a repairing composition for reducing senescence cell cumulant and a preparation method and application thereof, and the repairing composition comprises the following components in parts by weight: 0.01-7.0 parts of probiotic pellets PDRN, 0.01-3.0 parts of microspheroidized PDRN, 0.01-10.0 parts of a ginseng root extract, 0.01-10.0 parts of red ginseng fermented vesicles, a thickening agent, functional components and water. Under a formula system of a thickening agent and functional components, the probiotic pellets PDRN, the microspheroidized PDRN, the ginseng root extract and the red ginseng fermented vesicles are added, and all the components have a synergistic effect, so that the composition can penetrate into skin to achieve the effect of accurately repairing mitochondrial dysfunction, can directly remove senescent cells, reduces the senescent cell cumulant in a body in multiple ways, and has a good effect on repairing mitochondrial dysfunction. Therefore, the prepared skin care composition can effectively delay skin aging.

The invention relates to a drug combination composition for removing senescent cells and application of the drug combination composition. The drug combination composition comprises NK cells and calcium folinate. According to the invention, the NK cells and the calcium folinate are creatively combined. Tests show that compared with a use scheme of combining other medicines with the NK cells, the calcium folinate can remarkably improve the killing effect of the NK cells on senescent cells.

Machine learning techniques of characterizing senescence in an immobilized patient cell are disclosed. The techniques include: obtaining a patient cell image; passing the patient cell image to a trained machine learning system, where the trained machine learning system is trained using a training corpus that includes a plurality of training cell images, where the plurality of training cell images include a plurality of images of normal cells and a plurality of images of cells with senescence; obtaining an output from the trained machine learning model in response to the passing, where the output is indicative of a senescence property of the patient cell, and where the senescence property is non-binary; and providing an indication of the senescence property of the patient cell based on the output.

The invention relates to a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist for use in a method of treating a patient suffering from a tumour. The invention further relates to a pharmaceutical composition, comprising a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumour, and to a calcium homeostasis disruptor in combination with a selective DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.

The invention discloses a ternary fusion polypeptide Col-TF-1 targeting senescence cells, a monoclonal antibody mAb SC-1 matched with the ternary fusion polypeptide Col-TF-1, an anti-aging composition containing the ternary fusion polypeptide Col-TF-1 and the monoclonal antibody mAb SC-1, and application of the ternary fusion polypeptide Col-TF-1 The fusion polypeptide is formed by connecting a targeting peptide for targeting a senescence cell surface uPAR receptor, a collagen active peptide for promoting collagen synthesis and an immunomodulatory peptide for activating NK cells in series through a flexible linker GGGGS, and the amino acid sequence is as shown in SEQ ID NO.1. The invention further discloses a preparation method of the fusion polypeptide. Through CDR region humanized reconstruction and pH sensitive histidine switch design, the affinity of the matched antibody mAb SC-1 is improved by 5 times in a subacid environment, and the ADCC effect is enhanced through fucose-deficient host cells. Experiments show that when the fusion polypeptide is combined with the antibody, the senescent cell clearance rate can reach 45.2%, the collagen density is increased by 83.5%, and the effect is obviously superior to that of a single drug. The composition provided by the invention can be applied to the fields of cosmetics, medical instruments, medicines and functional foods, and provides a new strategy for treatment of senescence-related diseases and development of anti-senescence products.

Described herein are compositions for delaying onset or delaying progression of frailty, reversing aging phenotype, extending healthspan, compressing morbidity, increasing lifespan and reducing formation of senescent cells.

The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and / or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and / or detecting the amount and / or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.

The present invention discloses a photosensitizer prodrug compound (structural formula (I)) that selectively clears senescent cells and is specifically activated by the aging-associated β-galactosidase, as well as its preparation method and application. Upon activation by β-galactosidase, the compound rapidly releases its active molecule, anchoring it to proteins with nucleophilic groups. This allows for precise detection and covalent anchoring of senescent cells, thereby achieving selective clearance of senescent cells, reversing senescence-related markers and gene expression, and ameliorating aging-related decline in bodily functions. #imgabs0#

The invention discloses a preparation method of DRP1 engineered mitochondrial derived vesicles and application of the DRP1 engineered mitochondrial derived vesicles in cell aging resistance. The method comprises the following steps: firstly, constructing a lentiviral vector of an overexpressed DRP1 gene, and transfecting cells to obtain a cell strain of the stable overexpressed DRP1 gene; and culturing the cell strain, collecting a culture solution, and separating and extracting the mitochondrial derived vesicles to obtain the DRP1 engineered mitochondrial derived vesicles DRP1-MDVs rich in mtDNA. The DRP1-MDVs is used for treating senescent cells, the DRP1-MDVs is successfully internalized into senescent cells, the ROS level can be effectively reduced, the mitochondrial mtDNA and ATP content can be improved, the mtDNA mutation rate can be reduced, the mitochondrial membrane potential and the mitochondrial network structure can be recovered, and finally the expression of senescence-related proteins P16 and P21 can be reduced. The obvious mitochondrial function repairing potential and the cell aging improving effect are shown.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to the use of GRP78 and peptides similar thereto or nucleic acids encoding the same. The peptides or nucleic acids according to the present invention can increase the expression of biomarkers having reduced expression in senescent cells, and thus can be used to restore the function of muscle tissue that has decreased in function due to aging, etc.